Basic & Clinical Medicine ›› 2013, Vol. 33 ›› Issue (8): 992-997.

Previous Articles     Next Articles

The effect of lidamycin against mouse myeloma in vivo and in vitro


  • Received:2012-07-02 Revised:2012-09-24 Online:2013-08-05 Published:2013-07-18
  • Supported by:
    Studies on the mechanisms of lidamycin and its combination with bortezomib against multiple myeloma

Abstract: Objective This study is to investigate the effect of Lidamycin (LDM) against mouse myeloma in vivo and in vitro and provide the basis for its use in therapy. Methods MTS assay was used to detect SP2/0 cell proliferation. Cell cycle distribution and cell apoptosis were measured by flow cytometry combined with propidium iodide (PI) staining. The expression of proteins was determined by Western blot analysis. In vivo antitumor activity was performed using a murine myeloma model in BALB/c mice. Results There was a significant reduction of proliferation in the cells treated with LDM. The overall growth inhibition correlated with apoptotic cell death. LDM induced cell apoptosis was associated with decrease of NF-κB, Bcl-2, and Survivin. LDM induced G2/M phase arrest through increase the expression of p27 protein in SP2/0 cells. LDM markedly suppressed tumor growth in murine myeloma model. Conclusion LDM demonstrates a significant antitumor efficacy against myeloma SP2/0 in vivo and in vitro. Taken together, our data provided some clues for further research of the effects of LDM on human multiple myeloma.

Key words: Lidamycin, cell apoptosis, mouse myelom, Anti-tumor

CLC Number: